BENITEC BIOPHARMA INC (BNTC) — insider trading
Health Care · NASDAQ
BENITEC BIOPHARMA INC (BNTC) has 21 reported SEC Form 4 insider transactions in our data, including 12 open-market purchases among the most recent 21 (latest 2026-06-29).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | BUCHI J KEVIN | Director | Bona fide gift | 51,813 | $0.00 | $0 | Form 4 |
| 2026-05-26 | Friedman David Matthew | Director | Grant / award / vesting (derivative) | 35,000 | $0.00 | $0 | Form 4 |
| 2026-01-22 | Mates Sharon | Director | Grant / award / vesting (derivative) | 31,500 | $0.00 | $0 | Form 4 |
| 2025-12-29 | SUVRETTA CAPITAL MANAGEMENT, LLC; Cowen Aaron; Averill Master Fund, Ltd.; Averill Madison Master Fund, Ltd. | Director, 10% owner | Open-market purchase | 11,587 | $13.44 | $155.7K | Form 4 |
| 2025-12-29 | SUVRETTA CAPITAL MANAGEMENT, LLC; Cowen Aaron; Averill Master Fund, Ltd.; Averill Madison Master Fund, Ltd. | Director, 10% owner | Open-market purchase | 65,800 | $13.44 | $884.4K | Form 4 |
| 2025-12-26 | SUVRETTA CAPITAL MANAGEMENT, LLC; Cowen Aaron; Averill Master Fund, Ltd.; Averill Madison Master Fund, Ltd. | Director, 10% owner | Open-market purchase | 2,516 | $13.10 | $33.0K | Form 4 |
| 2025-12-26 | SUVRETTA CAPITAL MANAGEMENT, LLC; Cowen Aaron; Averill Master Fund, Ltd.; Averill Madison Master Fund, Ltd. | Director, 10% owner | Open-market purchase | 14,320 | $13.10 | $187.6K | Form 4 |
| 2025-12-23 | SUVRETTA CAPITAL MANAGEMENT, LLC; Cowen Aaron; Averill Master Fund, Ltd.; Averill Madison Master Fund, Ltd. | Director, 10% owner | Open-market purchase | 7,400 | $12.85 | $95.1K | Form 4 |
| 2025-12-23 | SUVRETTA CAPITAL MANAGEMENT, LLC; Cowen Aaron; Averill Master Fund, Ltd.; Averill Madison Master Fund, Ltd. | Director, 10% owner | Open-market purchase | 42,600 | $12.85 | $547.4K | Form 4 |
| 2025-12-22 | SUVRETTA CAPITAL MANAGEMENT, LLC; Cowen Aaron; Averill Master Fund, Ltd.; Averill Madison Master Fund, Ltd. | Director, 10% owner | Open-market purchase | 2,892 | $12.08 | $34.9K | Form 4 |
| 2025-12-22 | SUVRETTA CAPITAL MANAGEMENT, LLC; Cowen Aaron; Averill Master Fund, Ltd.; Averill Madison Master Fund, Ltd. | Director, 10% owner | Open-market purchase | 16,650 | $12.08 | $201.1K | Form 4 |
| 2025-12-19 | SUVRETTA CAPITAL MANAGEMENT, LLC; Cowen Aaron; Averill Master Fund, Ltd.; Averill Madison Master Fund, Ltd. | Director, 10% owner | Open-market purchase | 2,434 | $11.48 | $27.9K | Form 4 |
| 2025-12-19 | SUVRETTA CAPITAL MANAGEMENT, LLC; Cowen Aaron; Averill Master Fund, Ltd.; Averill Madison Master Fund, Ltd. | Director, 10% owner | Open-market purchase | 13,950 | $11.48 | $160.1K | Form 4 |
| 2025-12-18 | SUVRETTA CAPITAL MANAGEMENT, LLC; Cowen Aaron; Averill Master Fund, Ltd.; Averill Madison Master Fund, Ltd. | Director, 10% owner | Open-market purchase | 1,515 | $11.24 | $17.0K | Form 4 |
| 2025-12-18 | SUVRETTA CAPITAL MANAGEMENT, LLC; Cowen Aaron; Averill Master Fund, Ltd.; Averill Madison Master Fund, Ltd. | Director, 10% owner | Open-market purchase | 8,700 | $11.24 | $97.8K | Form 4 |
| 2025-12-01 | BUCHI J KEVIN | Director | Grant / award / vesting (derivative) | 35,000 | $0.00 | $0 | Form 4 |
| 2025-12-01 | Francis Peter | Director | Grant / award / vesting (derivative) | 35,000 | $0.00 | $0 | Form 4 |
| 2025-12-01 | Smith Edward F | Director | Grant / award / vesting (derivative) | 35,000 | $0.00 | $0 | Form 4 |
| 2025-12-01 | Mehta Kishan | Director | Grant / award / vesting (derivative) | 35,000 | $0.00 | $0 | Form 4 |
| 2025-12-01 | Mates Sharon | Director | Grant / award / vesting (derivative) | 3,500 | $0.00 | $0 | Form 4 |
| 2025-11-18 | Mukadam Sophie | Officer (Chief Operating Officer) | Grant / award / vesting (derivative) | 500,000 | $0.00 | $0 | Form 4 |
Ask the chat about BNTC's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: BENITEC BIOPHARMA INC (BNTC).
Last updated 2026-06-29 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.